Foghorn Therapeutics Inc FHTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-23 |
| Shares Out. | 58,710,000 |
| Website | foghorntx.com/ ↗ |
| Phone | 16175863100 |
| Employees | 106 |
| Revenue | $3.3M |
| Gross Profit | $3.3M |
| Net Income | -$19.9M |
| Free Cash Flow | -$87.4M |
| Total Assets | $222.2M |
| Total Liabilities | $298.6M |
| Equity | -$76.4M |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Foghorn Therapeutics Inc is a publicly traded company under the ticker symbol FHTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)